On June 27, 2022 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that members of its management team will present at the following industry conferences in Europe (Press release, Compugen, JUN 27, 2022, View Source [SID1234616305]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Event: 10th Antibody Industrial Symposium, Montpellier, France
Date: Tuesday June 28, 2022
Presenter: Pierre Ferré, Ph.D., VP, Preclinical Development, Compugen
Presentation track: IO mAb targets – BsAbs – Fc-fusion protein/ Rare Diseases
Presentation title: PVRIG and TIGIT immune checkpoint blockade in cancer: Emerging translational data from clinical trials
Event: Immuno UK, London, UK
Dates: Thursday September 29 and Friday September 30, 2022
Presenter: Eran Ophir, Ph.D., SVP, Research and Drug Discovery, Compugen
Presentation track: Discovery & Development: Intratumoral Immunotherapies & Antibody Therapies
Presentation title: Potential of PVRIG and TIGIT blockade in addressing immunotherapy resistance
Panel Discussion: Combinatorial Strategies in Immuno-Oncology
Slides will be accessible on the publication section of the Compugen website at www.cgen.com